Drug major Cipla slashed the price of three cancer drugs. In May, YK Hamied, Chairman and managing director of Cipla had promised that to continue slashing the price of its cancer drugs. The new drugs cost 50-64% less than its
Indian pharma companies are really making strides in the US market. Hyderabad-based drug major Dr Reddy's Laboratories on Monday said it had launched anti-osteoporosis drug Ibandronate Sodium in tablet form and 150 mg dosage in
When Cipla, the second largest pharma company in India, announced that it is slashing prices of three anti-cancer drugs used to treat brain, lung and kidney cancer it sent shockwaves in the pharma world.
Cipla’s move will
Bayer AG isn’t going to take the compulsory licensing verdict lying down. In March, the Indian Patent Office, in a game-changing ruling allowed Natco, an Indian firm to replicate Bayer’s blockbuster cancer drug Nexavar. This
Cipla, one of the biggest Indian pharmaceutical companies today announced that they have reduced the price of the generic drug, Soranib from Rs 28,000 to Rs 6,840, a decrease of almost 80%. This move seems to be influenced by the
On Friday Swiss drugmaker Roche Holding announced plans to launch two cut-price blockbuster cancer drugs for the Indian market soon. Roche, the world’s biggest maker of cancer drugs, said it would offer “significantly”